BioSpace News Archive

Invacare Corporation to Participate in the 5 th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference

The SebastianStrong Foundation has selected Yale Cancer Center’s Ranjithmenon Muraleedharan, M.D., as the recipient of the organization’s 2020 Discovery Science Award.

Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology company, announced that the NIH awarded CTT $1.44M on the second year of a competitive Small Business Innovation Research (SBIR) Phase IIB grant. The three year grant commenced in 2019 and totals $3.3M and this second year of funding supports the current CTT1403 clinical trial. The clinical trial, conducted at University of California, San Francis

- Biohaven will receive up to $250 million to fund zavegepant’s development in migraine and non-migraine indications - Royalty Pharma to acquire up to a 3% royalty for zavegepant, a 0.4% royalty of Nurtec™ ODT and success-based milestone payments - Royalty Pharma will purchase new Commercial Launch Preferred Equity from Biohaven for a total of $200 million payable between 2021 and 2024, providing additional funding for its CGRP-targeting franchise

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) (“Biohaven” or the “Company”) announced that it entered into a $500 million non-dilutive term loan financing facility with Six

InnovHeart s.r.l. , a developer of novel Transcatheter Mitral Valve Replacement (TMVR) systems for the treatment of mitral valve disease, announced today the closing of a €20 million round of equity financing. Founded in 2015 by Giovanni Righini , a 30-year veteran of the heart valve industry, the company maintains offices outside Milan, Italy, and Boston, Massachusetts. Proceeds from the financing will be used to

Texas Cardiac Arrhythmia Institute at St.

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Rare Pediatric Disease Designation (RPDD) to Kazia’s paxalisib (formerly GDC-0084) for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG)

Amerijet International Airlines has completed its IATA CEIV Pharma re-certification for the handling of temperature-controlled healthcare and life science products.

Anderson will support the company’s response to the rapid need for remote site access and collaboration platforms